Сучасні погляди на діагностику та лікування пролактином
DOI:
https://doi.org/10.24026/1818-1384.3(44).2013.77711Ключові слова:
prolactin, prolactinoma, dopamine agonists, cabergolinАнотація
Recent trends in diagnostics and treatment of prolactinomas were reviewed. The advantages and disadvantages of surgical and pharmaceutical methods in treatment as well as the rate of radiotherapy in complex therapy of prolactinomas were discussed. High efficiency of selective agonist dopamine allows considering it as alternative to surgical treatment. The new remedies for organic hyperprolactinemia: somatostatin analogues, estrogen receptors modulators, prolactine receptor antagonists were under exploration. The ways of high dose dopamine agonists intolerance and resistance overcoming were under discussion.
Посилання
Prolactin enhances CCAAT enhancer-binding protein-beta (C/EBP beta) and peroxisome proliferator-activated receptor gamma (PPAR gamma) messenger RNA expression and stimulates adipogenic conversion of NIH-3T3 cells [Text] / R. Nanbu-Wakao, Y. Fujitani, Y. Masuho [et al.] // Molec. Endocrinol. – 2000. – №14. – P. 307-316. https://doi.org/10.1210/mend.14.2.0420
Horseman, N.D. Prolactin [Text] / N.D. Horseman. – Boston: Kluwer Acad. Publ., 2001. – 184 p.
Kooijman R. Prolactin, growth hormone, and insulin-like growth factor-1 in the immune system [Text] / R. Kooijman, E.L. Hooghe-Peters, R. Hooghe // Adv. Immunol. – 1996. – №63. – P. 377-454. https://doi.org/10.1016/s0065-2776(08)60860-3
Yu-Lee, L.Y. Prolactin Modulation of Immune and Inflammatory Responses [Text] / L.Y. Yu-Lee // Recent. Prog. Horm. Res. – 2002. – №57. – P. 435-455. https://doi.org/10.1210/rp.57.1.435
Вознюк Н.Е. Пролактиномы и гиперпролактинемия: обзор [Текст ] / Н.Е. Вознюк, Л.Г. Старикова, В.А. Хоружая // Вестн. новых мед. технологий. – 2000. – №12. – С. 97-100.
Development and potential clinical uses of human prolactin receptor antagonists [Text] / V. Goffin, S. Bernichtein, P. Touraine, P.A. Kelly // Endocr. Rev. – 2005. – №26. – P. 400-422. https://doi.org/10.1210/er.2004-0016
Дедов И.И. Акромегалия: патогенез, клиника, диагностика, дифференциальная диагностика, методы лечения [Текст]: пособие для врачей / И.И. Дедов, Н.Н. Молитвословова, Е.И. Марова; под ред. И.И. Дедова. - Тверь: ООО «Издательство «Триада», 2003. - 40 с.
BMI and Metabolic Profile in Patients With Prolactinoma Before and After Treatment With Dopamine Agonists [Електронний ресурс] / C.M. Dos Santos Silva [et al.] // Obesity. – 2010. – Режим доступу: http://www.ncbi.nlm.nih.gov/pubmed/20559294 https://doi.org/10.1038/oby.2010.150
Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy [Електронний ресурс] / K. Berinder, T. Nystrom, C. Hoybye [et al.] // Pituitary. – 2010. – Режим доступу: http://www.ncbi.nlm.nih.gov/pubmed/21128120 https://doi.org/10.1007/s11102-010-0277-9
Insulin sensitivity and hyperprolactinemia [Text] / A. Tuzcu, M. Bahceci, M. Dursun [et al.] // J. Endocrinol. Invest. – 2003. – Vol. 26, №4. – P. 341-346. https://doi.org/10.1007/bf03345182
Пивоварова С.В. Менопаузальный синдром у больных с гиперпролактинемическим гипогонадизмом (клиника, диагностика, возможности применения заместительной гормональной терапии) [Текст]: автореф. дис. … канд. мед. наук: 14.00.03 / Пивоварова С.В. – М., 2002. – 20 с.
Осипова А.А. Избыточная масса тела и абдоминальный тип ожирения у пациенток с опухолевой и неопухолевой формами гиперпролактинемии; влияние терапии парлоделом, норпролаком и достинексом [Текст] / А.А. Осипова, В.П. Сметник // Пробл. репрод. – 2002. – №1. – С. 12-17.
Verhelst J. Hyperprolactinemia: pathophysiology and management [Text] / J. Verhelst, R. Abs // Treat. Endocrinol. – 2003. – Vol. 2, №1. – P. 23-32. https://doi.org/10.2165/00024677-200302010-00003
Корнеева И.Е. Клиника, диагностика и лечение бесплодия у женщин с функциональной гиперпролактинемией [Текст]: автореф. дис. … канд. мед. наук: 14.00.01 / Корнеева И.Е.; Науч. Центр акушерства, гинекологии и перинатологии. – М., 2003. – 20 с.
Shibli-Rahhal A., Schlechte J. Hyperprolactinemia and infertility [Text] / Endocrinol. Metab. Clin. North Am. – 2011. – Vol. 40, № 4. – P. 837-846. https://doi.org/10.1016/j.ecl.2011.08.008
Дедов И.И. Персистирующая галакторея-аменорея [Текст] / И.И. Дедов, Г.А. Мельниченко. – М.: Медицина, 1985. – 256 с.
Марова Е.И. Нейроэндокринология [Текст] / Е.И. Марова. – Ярославль: [б.и.], 1999. – 506 с.
Кравчун Н.А. Гиперпролактинемические состояния [Текст] / Н.А. Кравчун / 100 избранных лекций по эндокринологии / под ред. Ю.И. Караченцева, А.В. Казакова, Н.А. Кравчун, И.М. Ильиной. – Х., 2009. – С. 842-847.
Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia[Text] / M. Kars [et al.] // J. Clin. Endocrinol. Metabol. – 2009. – Vol. 94, No 8. – P. 2729-2734. https://doi.org/10.1210/jc.2009-0177
Update in prolactinomas [Text] / M. Kars [et al.] // Netheland J. Med. – 2010. – Vol. 68, №3. – P. 104-112. http://www.njmonline.nl/article.php?a=897&d=567&i=124
Outcome of transsphenoidal surgery for acromegaly and its relationship to surgical experience [Text] / S. Ahmed, M. Elsheikh, B.C.X. Page [et al.] // Clin. Endocrinol. – 1999. – 150. – P. 561-567. https://doi.org/10.1046/j.1365-2265.1999.00760.x
Beckers A. Approaching the true prevalence of pituitary tumors [Text] / A. Beckers, C. Adam, A. Ciccarelli [et al.] // ENEA abstr. Congress, Sorrento (Naples), 24-27 apr. 2004. – Sorrento, 2004. – P. 23.
Vance M.L. Hyperprolactinemic syndromes and management [Text] / M.L. Vance, M.O. Thorner. – 2nd ed. – Philadelphia, [etc.]: WB Saunders Company, 1989. – P. 408-418.
Colao A. Growth-hormone and prolactin excess [Text] / A. Colao, G. Lombardi // Lancet. – 1998. – Vol. 352. – P. 1455-1461. https://doi.org/10.1016/s0140-6736(98)03356-x
Мельниченко Г.А. Гиперпролактинемические состояния: клиника, диагностика, лечение [Текст] / Г.А. Мельниченко, Т.Н. Романцова // Врач. - 1999. - №1. - С. 10-14.
Овсянникова Т.В. Патогенез, клиника, диагностика и отдаленные результаты лечения бесплодия при гиперпролактинемии у женщин [Текст]: автореф. дис. … д-ра мед. наук: 14.00.03 / Овсянникова Т.В.; Центр репродуктивного здоровья. – М., 1990. – 40 с.
Вакс В.В. Гипогонадотропный гипогонадизм у мужчин[Текст] / В.В. Вакс // Актуальные проблемы нейроэндокринологии: материалы II Всерос. науч.-практ. конф., – М., 2001. – С. 73-84.
Kleinberg D.L. Galactorrhea: a study of 235 cases, including 48 with pituitary tumors [Text] / D.L. Kleinberg, G.L. Noel, A.G. Frantz // N. Engl. J. Med. – 1977. – №296. – P. 589-600. https://doi.org/10.1056/nejm197703172961103
Schlechte J.A. Long-Term Management of Prolactinomas [Text] / J.A. Schlechte // J. Clin. Endocrinol.Metabol. – 2007. – Vol. 92, No 8. – P. 2861-2865. https://doi.org/10.1210/jc.2007-0836
Guidelines of the piuitary Society for the diagnosis and management of prolactinomas [Text] /F. Casanueva, M. Molitch, J. Schlechte [et al.] // Clin. Endocrinol. – 2006. – №65. – P. 265-273. https://doi.org/10.1111/j.1365-2265.2006.02562.x
Drug insight: cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women [Text] / A. Colao, A. Di Sarno, E. Guerra [et al.] // J. Clin. Endocrinol. Metabol. – 2006. – Vol. 2, №4. – P. 200-210. https://doi.org/10.1038/ncpendmet0160
St-Jean E. High prolactin levels may missed by immunoradiometric assay in patients with macroprolactinomas [Text] / E. St-Jean, F. Blain, R. Comtois // Clin. Endocrinol. – 1996. – Vol. 44, №3. – P. 305. https://doi.org/10.1046/j.1365-2265.1996.663486.x
Schlechte J.A. Prolactinoma [Text] / J.A. Schlechte // N. Engl. J. Med. – 2003. – Vol. 349. – P. 2035-2041. https://doi.org/10.1056/nejmcp025334
Whitehead S., Miell J. Clinical Endocrinology [Text] / Whitehead S., Miell J. – Scion Publishing, 2013. – P. 49-107.
Mindermann T. Age-related and gender-related occurrence of pituitary adenomas [Text] / T. Mindermann, C.B. Wilson // Clin. Endocrinol. (Oxf.).- 1994. – Vol. 41, №3. – P. 359-364. https://doi.org/10.1111/j.1365-2265.1994.tb02557.x
Acromegaly. A handbook of history, current therapy and future prospects [Text] / Ed. J. Wass. – [S.I.]: BioScientifica, 2009. – P. 137-153.
Dusek T. Transsphenoidal surgery for pituitary adenoma: indications and outcomes [Text] / Dusek T., Melada A., Paladino J., Kastelan D./ Croat. Med. J. – 2012. – Vol. 53, № 6. – P. 639-640. https://doi.org/10.3325/cmj.2012.53.639
Molitch M.E. Medical management of prolactin-secreting pituitary adenomas [Text] / M.E. Molitch // Pituitary. – 2002. – №5. – P. 55-65. https://doi.org/10.1023/a:1022375429083
Hardy J. Transsphenoidal microsurgery of prolactinomas: report on 355 cases [Text] / J. Hardy // Prolactin Prolactinomas / Ed. by G. Tolis, C. Stefanis, T. Mountokalakis [et al.]. – New York, 1983. – P. 431-440.
Dolenc V.V. Transcranial epidural approach to pituitary tumors extending beyond the sella [Text] / V.V. Dolenc // Neurosurgery. – 1997. – Vol. 41. – P. 542-552. https://doi.org/10.1097/00006123-199709000-00007
Jane J.A. The surgical management of pituitary adenomas in series of 3093 patients [Text] / J.A. Jane, E.R. Laws // J. Amer. Coll. Surg. – 2001. – Vol. 193. – P. 651-659. https://doi.org/10.1016/s1072-7515(01)01101-2
Laws E.R. Pituitary surgery [Text] / E.R. Laws, K. Thapar // Endocrinol. Metabol. Clin. N. Amer. – 1999. – №28. – P. 119-131. https://doi.org/10.1016/s0889-8529(05)70059-1
Drug insight: cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women [Text] / A. Colao, A. Di Sarno, E. Guerra [et al.] // J. Clin. Endocrinol. Metabol. – 2006. – Vol. 2, №4. – P. 200-210. https://doi.org/10.1038/ncpendmet0160
Mann W.A. Treatment for prolactinomas and hyperprolactinaemia: a lifetime approach [Text] // Eur. J. Clin. Invest. – 2011. – Vol. 41, № 3. – P. 334-342. https://doi.org/10.1111/j.1365-2362.2010.02399.x
Melmed S. Mechanisms for pituitary tumori genesis: the plastic pituitary [Text] / S. Melmed // J. Clin. Invest. – 2003. – №112. – P. 1603-1618. https://doi.org/10.1172/jci20401
Crosignani P.G. Current treatment issues in female hyperprolactinaemia [Text]: Review / P.G. Crosignani // Europ. J. Obstetr. Gynecol. Reproduct. Biol. – 2005. – №4. – P. 13. https://doi.org/10.1016/j.ejogrb.2005.10.005
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas [Text] / F. Casanueva, M. Molitch, J. Schlechte [et al.] // Clin. Endocrinol. (Oxf.). – 2006. – №65. – P. 265-273. https://doi.org/10.1111/j.1365-2265.2006.02562.x
Abboud C.H. Prolactinomas [Text] / C.H. Abboud, M. Ebersold // Diagnosis and Management Pituitary Tumors. – 2001. – P. 279-294. https://doi.org/10.1385/1-59259-217-1:279
Diagnosis & treatment of hyperprolactinemia: An Endocrine Society Clinical Practice Guideline [Text] / S. Melmed, F. Casanueva, R. Andrew [et al.] // J. Clin. Endocrinol. Metabol. – 2011. – Vol. 96, №2. – P. 273-288. https://doi.org/10.1210/jc.2010-1692
Individualized High-Dose Cabergoline Therapy for Hyperprolactinemic Infertility in Women with Micro- and Macroprolactinomas [Text] / O. Masami, M. Nobuhiro, A. Kosaku [et al.] // J. Clin. Endocrinol. Metab. – 2010. – Vol. 95, №6. – P. 2672-2679. https://doi.org/10.1210/jc.2009-2605
Бондаренко Л.И. Достигекс: консервативное лечение пролактином гипофиза [Текст] / Л.И. Бондаренко, Е.В. Иващенко // Здоровье женщины. – 2005. – №1. – С. 121-126.
Sandret I. Treatment of Acromegaly with Cabergoline [Text] / I. Sandretet [et al.] // J. Clin. Endocrinol. Metab. – 2011. – Vol. 96, №5. – P.1327-1335. https://doi.org/10.1210/jc.2010-2443
Shimon I. Effectiveness of long-term cabergoline treatment for giantprolactinoma: study of 12 men [Text] / I. Shimon, C. Benbassat, M. Hadani // Europ. J. Endocrinol. – 2007. – №156. – P. 225-231. https://doi.org/10.1530/eje-06-0646
Cabergoline therapy of growth hormone, growth hormone / prolactin secreting pituitary tumors [Text] / P. Freda, C. Reyes, A. Nuruzzaman [et al.] // Pituitary. – 2004. – №7. – P. 21-30. https://doi.org/10.1023/b:pitu.0000044630.83354.f0
Outcome of Cabergoline treatment in men with prolactinoma: Effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis [Text] / A. Colao, G. Vitale, P. Cappabianca [et al.] // J. Clin. Endocrinol. Metabol. – 2004. – Vol. 89, №4. – P. 1704-1711. https://doi.org/10.1210/jc.2003-030979
Guitelman M. Long-term follow-up of prolactinomas: should dopamine agonist treatment be life-long? [Text] / Guitelman, M. // Front. Horm. Res. – 2006. – №35. – P. 88-101. https://doi.org/10.1159/000094312
Colao A., Savastano S. Medical treatment of prolactinomas [Text] // Nat. Rev. Endocrinol. – 2011. – Vol. 7, № 5. – P. 267-278. https://doi.org/10.1038/nrendo.2011.37
Delgrange E. Influence of parasellar extension of macrolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy [Text] / E. Delgrange, T. Duprez, D. Maiter // Clin. Endocrinol. – 2006. – № 64. – P. 456-462. https://doi.org/10.1111/j.1365-2265.2006.02493.x
Fusco A. Prognostic Significance of the Ki-67 Labeling Index in Growth Hormone-Secreting Pituitary Adenomas [Text] / A. Fusco, M. Zatelli, A. Bianchi [et al.] // J. Clin. Endocrinol. Metabol. – 2008. – Vol. 93, №7. – P. 2746-2750. https://doi.org/10.1210/jc.2008-0126
Clemmons D. Hot topic in pituitary tumor management. Perspectives [Text] / D. Clemmons, L. Nieman, J. Schlechte // Endocr. News. – 2006. – №7. – P. 17-21.
Sedda A. Management of prolactinomas: what's new in 2010? [Text] / A. Sedda, P. Meyer // Rev. Med. Suisse. – 2011. – Vol. 12, №7 (277). – P. 20-24.
PRL secreting adenomas in male patients [Text] / A. Ciccarelli, E. Guerra, M. De Rosa [et al.] // Pituitary. – 2005. – №8. – P. 39-42. https://doi.org/10.1007/s11102-005-5084-3
Pinero A. Cabergoline-related severe restrictive mitral regurgitation [Text] / A. Pinero, P. Marcos-Alberca, J. Fortes // N. Engl. J. – 2005. – №12. – P. 1976-1977. https://doi.org/10.1056/nejm200511033531822
Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required [Text] / M. Kars, A. Pereira, J. Bax, J. Romijn // Europ. J. Endocrinol. – 2008. – Vol. 159. – P. 363-367. https://doi.org/10.1530/eje-08-0611
Molitch M.E. Pharmacologic Resistance in Prolactinoma Patients [Text] / M. Molitch // Pituitary. – 2005. – №8. – P. 43-52. https://doi.org/10.1007/s11102-005-5085-2
Delgrange E. Influence of parasellar extension of macrolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy [Text] / E. Delgrange, T. Duprez, D. Maiter // Clin. Endocrinol. – 2006. – №64. – P. 456-462. https://doi.org/10.1111/j.1365-2265.2006.02493.x
Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas [Text] / L. Caccavelli, P. Jaquet, C. Kordon [et al.] // J. Neuroendocrinol. – 1996. – Vol. 10, №10. – P. 737-746. https://doi.org/10.1046/j.1365-2826.1996.04902.x
Resistance to Cabergoline as compared with bromocriptine in hyperprolactinemia prevalence, clinical definition, and therapeutic strategy [Text] / A. Di Sarno, M. Landi, P. Cappabianca [et al.] // J. Clin. Endocrinol. Metabol. – 2001. – Vol. 86, №11. – P. 5256-5261. https://doi.org/10.1210/jcem.86.11.8054
Delgrange E. Influence of parasellar extension of macrolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy [Text] / E. Delgrange, T. Duprez, D. Maiter // Clin. Endocrinol. – 2006. – №64. – P. 456-462. https://doi.org/10.1111/j.1365-2265.2006.02493.x
Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells [Text] / S. Lamberts, T. Verleun, L. Hofland, R. Oosterom // J. Clin. Endocrinol. Metabol. – 1986. – Vol. 63, №6. – P. 1342-1347. https://doi.org/10.1210/jcem-63-6-1342
Individualized High-Dose Cabergoline Therapy for Hyperprolactinemic Infertility in Women with Micro- and Macroprolactinomas [Text] / O. Masami, M. Nobuhiro, A. Kosaku [et al.] // J. Clin. Endocrinol. Metab. – 2010. – Vol. 95, №6. – P. 2672-2679. https://doi.org/10.1210/jc.2009-2605
Frequent Misdiagnosis and Mismanagement of Hyperprolactinemic Patients before the Introduction of Macroprolactin Screening: Application of a New Strict Laboratory Definition of Macroprolactinemia [Text] / A. Suliman, T. Smith, J. Gibney [et al.] // Clin. Chemistr. – 2003. – Vol. 49, №9. – P. 1504-1509. https://doi.org/10.1373/49.9.1504
Macroprolactinoma Shrinkage during Cabergoline Treatment Is Greater in Naive Patients Than in Patients Pretreated with Other Dopamine Agonists: A Prospective Study in 110 Patients [Text] / A. Colao, A. Di Sarno, M. Landi [et al.] // J. Clin. Endocrinol. Metabol. – 2000. – Vol. 85, №6. – P. 2247-2252. https://doi.org/10.1210/jcem.85.6.6657
Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists [Text] / D. Hamilton, M. Vance, P. Boulos [et al.] // Pituitary. – 2005. – Vol. 8, №1. – P. 53-60. https://doi.org/10.1007/s11102-005-5086-1
Lamberts S.W. Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas [Text] / S. Lamberts, T. Verleun, R. Oosterom // Neuroendocrinol. – 1982. – Vol. 34, №5. – P. 339-342. https://doi.org/10.1159/000123324
Effects of raloxifene, one of the selective estrogen receptor modulators, on pituitary-ovary axis and prolactin in postmenopausal women [Text] / W. Cheng, M. Yen, S. Hsu [et al.] // Endocrinology. – 2004. – Vol. 23, №2-3. – P. 215-218. https://doi.org/10.1385/endo:23:2-3:215
Development and potential clinical uses of human prolactin receptor antagonists [Text] / V. Goffm, S. Bernichtein, P. Touraine, P. Kelly // Endocr. Rev. – 2005. – Vol. 26, №3. – P. 400-422. https://doi.org/10.1210/er.2004-0016
SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile [Text] / C. Bruns, I. Lewis, U. Briner [et al.] // Europ. J. Endocrinol. – 2002. – Vol. 146. – P. 707-716. https://doi.org/10.1530/eje.0.1460707
Role of radiation therapy in clinical hormonally-active pituitary adenomas [Text] / R. Tsang, J. Brierley, T. Panzarella [et al.] // Radiother. Oncol. – 1996. – Vol. 41. – P. 45-53. https://doi.org/10.1016/s0167-8140(96)91807-1
A comparative evaluation of effectiveness of medical and surgical therapy in patients with macroprolactinoma [Text] / S. Acquati [et al.] // J. Neurosurg. Sci. – 2001. – Vol. 45, №2. – P. 65-69.
Oh M.C. Medical versus surgical management of prolactinomas [Text] / Oh M.C., Kunwar S., Blevins L., Aghi M.K. / Neurosurg. Clin. N. Am. – 2012. – Vol. 23, № 4. – P. 669-678. https://doi.org/10.1016/j.nec.2012.06.010
Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction [Text] / G. Corona [et al.] // J. Sex. Med. – 2009. – Vol. 6, № 5. – P. 1457-1466. https://doi.org/10.1111/j.1743-6109.2008.01206.x
Antonini A. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease [Text] / A. Antonini, W. Poewe // Lancet Neurol. – 2007. – Vol. 6, №9. – P. 826-829. https://doi.org/10.1016/s1474-4422(07)70218-1
Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required [Text] / M. Kars, A. M. Pereira, J.J. Bax, J.A. Romijn // Europ. J. Endocrinol. – 2008. – Vol. 159, №4. – P. 363-367. https://doi.org/10.1530/eje-08-0611
Vallette S. Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern? [Text] / S. Vallette, K. Serri, O. Serri // Expert. Rev. Cardiovasc. Ther. – 2010. – Vol. 8, №1. – P. 49-54. https://doi.org/10.1586/erc.09.167
Landberg E. Serum prolactin and macroprolactin in heart failure: no relation to established laboratory or clinical parameters [Text] / E. Landberg, U. Dahlstrom, U. Alehagen // Ann. Clin. Biochem. – 2011. – Vol. 48 (Pt 1). – P. 51-56. https://doi.org/10.1258/acb.2010.010164
##submission.downloads##
Опубліковано
Як цитувати
Номер
Розділ
Ліцензія
Авторське право (c) 2017 Клінічна ендокринологія та ендокринна хірургія
Ця робота ліцензується відповідно до Creative Commons Attribution-NonCommercial 4.0 International License.
